Literature DB >> 27040449

Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism.

Ilenia Minicocci1, Anna Tikka2, Eleonora Poggiogalle3, Jari Metso2, Anna Montali1, Fabrizio Ceci4, Giancarlo Labbadia1, Mario Fontana1, Alessia Di Costanzo1, Marianna Maranghi1, Aldo Rosano5, Christian Ehnholm2, Lorenzo Maria Donini3, Matti Jauhiainen2, Marcello Arca6.   

Abstract

The consequences of angiopoietin-like protein 3 (ANGPTL3) deficiency on postprandial lipid and lipoprotein metabolism has not been investigated in humans. We studied 7 homozygous (undetectable circulating ANGPTL3 levels) and 31 heterozygous (50% of circulating ANGPTL3 levels) subjects with familial combined hypolipidemia (FHBL2) due to inactivating ANGPTL3 mutations in comparison with 35 controls. All subjects were evaluated at fasting and during 6 h after a high fat meal. Postprandial lipid and lipoprotein changes were quantified by calculating the areas under the curve (AUCs) using the 6 h concentration data. Plasma changes of β-hydroxybutyric acid (β-HBA) were measured as marker of hepatic oxidation of fatty acids. Compared with controls, homozygotes showed lower incremental AUCs (iAUCs) of total TG (-69%, P < 0.001), TG-rich lipoproteins (-90%, P < 0.001), apoB-48 (-78%, P = 0.032), and larger absolute increase of FFA (128%, P < 00.1). Also, heterozygotes displayed attenuated postprandial lipemia, but the difference was significant only for the iAUC of apoB-48 (-28%; P < 0.05). During the postprandial period, homozygotes, but not heterozygotes, showed a lower increase of β-HBA. Our findings demonstrate that complete ANGPTL3 deficiency associates with highly reduced postprandial lipemia probably due to faster catabolism of intestinally derived lipoproteins, larger expansion of the postprandial FFA pool, and decreased influx of dietary-derived fatty acids into the liver. These results add information on mechanisms underlying hypolipidemia in FHBL2.
Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  familial combined hypolipidemia; free fatty acids; postprandial lipid metabolism

Mesh:

Substances:

Year:  2016        PMID: 27040449      PMCID: PMC4878193          DOI: 10.1194/jlr.P066183

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  51 in total

1.  Development of bioelectrical impedance analysis prediction equations for body composition with the use of a multicomponent model for use in epidemiologic surveys.

Authors:  Shumei S Sun; W Cameron Chumlea; Steven B Heymsfield; Henry C Lukaski; Dale Schoeller; Karl Friedl; Robert J Kuczmarski; Katherine M Flegal; Clifford L Johnson; Van S Hubbard
Journal:  Am J Clin Nutr       Date:  2003-02       Impact factor: 7.045

2.  International physical activity questionnaire: 12-country reliability and validity.

Authors:  Cora L Craig; Alison L Marshall; Michael Sjöström; Adrian E Bauman; Michael L Booth; Barbara E Ainsworth; Michael Pratt; Ulf Ekelund; Agneta Yngve; James F Sallis; Pekka Oja
Journal:  Med Sci Sports Exerc       Date:  2003-08       Impact factor: 5.411

3.  Chylomicron processing in familial dysbetalipoproteinemia and familial combined hyperlipidemia studied with vitamin A and E as markers: a new physiological concept.

Authors:  P N Demacker; M P Hectors; A F Stalenhoef
Journal:  Atherosclerosis       Date:  2000-03       Impact factor: 5.162

4.  Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.

Authors:  Kenichi Yoshida; Tetsuya Shimizugawa; Mitsuru Ono; Hidehiko Furukawa
Journal:  J Lipid Res       Date:  2002-11       Impact factor: 5.922

5.  Dietary determinants of serum paraoxonase activity in healthy humans.

Authors:  Paivi Kleemola; Riitta Freese; Matti Jauhiainen; Raija Pahlman; Georg Alfthan; Marja Mutanen
Journal:  Atherosclerosis       Date:  2002-02       Impact factor: 5.162

6.  Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.

Authors:  S Kersten; S Mandard; N S Tan; P Escher; D Metzger; P Chambon; F J Gonzalez; B Desvergne; W Wahli
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

7.  ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase.

Authors:  Tetsuya Shimizugawa; Mitsuru Ono; Mitsuru Shimamura; Kenichi Yoshida; Yosuke Ando; Ryuta Koishi; Kenjiro Ueda; Toshimori Inaba; Hiroyuki Minekura; Takafumi Kohama; Hidehiko Furukawa
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

8.  Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes.

Authors:  Mitsuru Shimamura; Morihiro Matsuda; Sachiko Kobayashi; Yosuke Ando; Mitsuru Ono; Ryuta Koishi; Hidehiko Furukawa; Makoto Makishima; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2003-02-07       Impact factor: 3.575

9.  Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.

Authors:  Marius R Robciuc; Marianna Maranghi; Anna Lahikainen; Daniel Rader; Andre Bensadoun; Katariina Öörni; Katariina Oörni; Jari Metso; Ilenia Minicocci; Ester Ciociola; Fabrizio Ceci; Anna Montali; Marcello Arca; Christian Ehnholm; Matti Jauhiainen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-09       Impact factor: 8.311

10.  Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor.

Authors:  Toshimori Inaba; Morihiro Matsuda; Mitsuru Shimamura; Norihide Takei; Naoki Terasaka; Yosuke Ando; Hiroaki Yasumo; Ryuta Koishi; Makoto Makishima; Iichiro Shimomura
Journal:  J Biol Chem       Date:  2003-04-01       Impact factor: 5.157

View more
  21 in total

1.  Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Authors:  Sergio Fazio; Jessica Minnier; Michael D Shapiro; Sotirios Tsimikas; Patrizia Tarugi; Maurizio R Averna; Marcello Arca; Hagai Tavori
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 2.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

3.  Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors:  Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal:  Expert Opin Ther Targets       Date:  2020-01-15       Impact factor: 6.902

Review 4.  Angiopoietin-like 3 in lipoprotein metabolism.

Authors:  Sander Kersten
Journal:  Nat Rev Endocrinol       Date:  2017-10-06       Impact factor: 43.330

5.  ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.

Authors:  Nathan O Stitziel; Amit V Khera; Xiao Wang; Andrew J Bierhals; A Christina Vourakis; Alexandra E Sperry; Pradeep Natarajan; Derek Klarin; Connor A Emdin; Seyedeh M Zekavat; Akihiro Nomura; Jeanette Erdmann; Heribert Schunkert; Nilesh J Samani; William E Kraus; Svati H Shah; Bing Yu; Eric Boerwinkle; Daniel J Rader; Namrata Gupta; Philippe M Frossard; Asif Rasheed; John Danesh; Eric S Lander; Stacey Gabriel; Danish Saleheen; Kiran Musunuru; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2017-04-03       Impact factor: 24.094

6.  Effect of meal composition on postprandial lipid concentrations and lipoprotein particle numbers: A randomized cross-over study.

Authors:  Meena Shah; Manall Jaffery; Beverley Adams-Huet; Brian Franklin; Jonathan Oliver; Joel Mitchell
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

Review 7.  New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

Authors:  Xin Su; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2018-01-15       Impact factor: 3.876

8.  Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation.

Authors:  Anna Cinkajzlová; Miloš Mráz; Zdeňka Lacinová; Jana Kloučková; Petra Kaválková; Helena Kratochvílová; Pavel Trachta; Jarmila Křížová; Denisa Haluzíková; Jan Škrha; Hana Papežová; Martin Haluzík
Journal:  Nutr Diabetes       Date:  2018-04-25       Impact factor: 5.097

Review 9.  Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

Authors:  Oluwayemisi Esan; Anthony S Wierzbicki
Journal:  Drug Des Devel Ther       Date:  2020-07-06       Impact factor: 4.162

10.  High-Serum Angiopoietin-Like Protein 3 Levels Associated with Cardiovascular Outcome in Patients with Coronary Artery Disease.

Authors:  Ming-Chun Chen; Bang-Gee Hsu; Chung-Jen Lee; Ji-Hung Wang
Journal:  Int J Hypertens       Date:  2020-03-27       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.